Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 59Neoplasm Metastasis 24Stomach Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Colorectal Neoplasms 10Neoplasms 8Brain Neoplasms 7Triple Negative Breast Neoplasms 5Adenocarcinoma 5Recurrence 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Advanced Solid Tumor 3Salivary Gland Neoplasms 2Meningeal Carcinomatosis 2HER2-positive Breast Cancer 2Colonic Neoplasms 2Breast Cancer With Brain Metastasis 2Adenocarcinoma Of Esophagus 2Uterine Neoplasms 1Unresectable Locally Recurrent Breast Cancer 1Solid Cancer 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Osteosarcoma 1Neoplasm, Residual 1

Interventions

trastuzumab deruxtecan 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × HER2-Positive Primary Breast Cancer × trastuzumab deruxtecan × Clear all
NCT04622319 2026-05-15

DESTINY-Breast05

Daiichi Sankyo

Phase 3 Active not recruiting
1,600 enrolled 1 FDA
Breast

HER2-Positive Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡